Craig A. Wheeler Sells 1,773 Shares of Momenta Pharmaceuticals, Inc. (MNTA) Stock

Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) CEO Craig A. Wheeler sold 1,773 shares of Momenta Pharmaceuticals stock in a transaction on Monday, February 12th. The shares were sold at an average price of $16.18, for a total transaction of $28,687.14. Following the completion of the sale, the chief executive officer now directly owns 258,713 shares in the company, valued at approximately $4,185,976.34. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Craig A. Wheeler also recently made the following trade(s):

  • On Tuesday, November 21st, Craig A. Wheeler sold 4,116 shares of Momenta Pharmaceuticals stock. The shares were sold at an average price of $13.35, for a total transaction of $54,948.60.

Shares of Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) traded up $0.25 on Wednesday, reaching $16.25. 934,334 shares of the company’s stock traded hands, compared to its average volume of 927,339. Momenta Pharmaceuticals, Inc. has a 52 week low of $11.85 and a 52 week high of $19.46. The firm has a market cap of $1,240.00, a PE ratio of -20.31 and a beta of 1.80.

MNTA has been the topic of a number of research analyst reports. Zacks Investment Research raised shares of Momenta Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, January 2nd. BidaskClub cut shares of Momenta Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, December 7th. Cowen set a $15.00 target price on shares of Momenta Pharmaceuticals and gave the stock a “hold” rating in a research note on Wednesday, November 1st. Finally, Stifel Nicolaus reaffirmed a “hold” rating and set a $18.00 target price on shares of Momenta Pharmaceuticals in a research note on Tuesday, January 30th. Two investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and one has given a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus price target of $15.30.

A number of institutional investors and hedge funds have recently made changes to their positions in MNTA. Tocqueville Asset Management L.P. boosted its stake in Momenta Pharmaceuticals by 243.6% during the 4th quarter. Tocqueville Asset Management L.P. now owns 963,784 shares of the biotechnology company’s stock worth $13,445,000 after purchasing an additional 683,296 shares during the last quarter. Renaissance Technologies LLC boosted its stake in Momenta Pharmaceuticals by 186.4% during the 2nd quarter. Renaissance Technologies LLC now owns 797,400 shares of the biotechnology company’s stock worth $13,476,000 after purchasing an additional 519,000 shares during the last quarter. Vanguard Group Inc. boosted its stake in Momenta Pharmaceuticals by 4.9% during the 2nd quarter. Vanguard Group Inc. now owns 6,243,767 shares of the biotechnology company’s stock worth $105,519,000 after purchasing an additional 290,090 shares during the last quarter. State Street Corp boosted its stake in Momenta Pharmaceuticals by 8.1% during the 2nd quarter. State Street Corp now owns 2,653,427 shares of the biotechnology company’s stock worth $44,842,000 after purchasing an additional 197,978 shares during the last quarter. Finally, Sectoral Asset Management Inc boosted its stake in Momenta Pharmaceuticals by 34.3% during the 4th quarter. Sectoral Asset Management Inc now owns 500,298 shares of the biotechnology company’s stock worth $6,979,000 after purchasing an additional 127,799 shares during the last quarter. 93.01% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION WARNING: This report was originally posted by American Banking News and is the property of of American Banking News. If you are accessing this report on another publication, it was stolen and republished in violation of US & international copyright laws. The legal version of this report can be read at https://www.americanbankingnews.com/2018/02/14/craig-a-wheeler-sells-1773-shares-of-momenta-pharmaceuticals-inc-mnta-stock.html.

About Momenta Pharmaceuticals

Momenta Pharmaceuticals, Inc is a biotechnology company. The Company is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. The Company has developed generic version of LOVENOX (enoxaparin sodium injection) and COPAXONE (glatiramer acetate injection).

Insider Buying and Selling by Quarter for Momenta Pharmaceuticals (NASDAQ:MNTA)

Receive News & Ratings for Momenta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply